Article Text

Download PDFPDF
Gastrointestinal stromal tumour treated with neoadjuvant imatinib
  1. M B Loughrey1,
  2. C Mitchell1,
  3. G B Mann2,
  4. M Michael3,
  5. P M Waring1
  1. 1Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC 3002, Australia
  2. 2Department of Surgical Oncology, Peter MacCallum Cancer Centre
  3. 3Department of Medical Oncology, Peter MacCallum Cancer Centre
  1. Correspondence to:
 Dr M B Loughrey
 Department of Pathology, Peter MacCallum Cancer Centre, St Andrew’s Place, East Melbourne, VIC 3002, Australia;


This report describes a case of unresectable primary gastrointestinal stromal tumour (GIST) treated with imatinib on a neoadjuvant basis, before subsequent successful surgical resection. After six months of imatinib, computed tomography and positron emission tomography imaging demonstrated a significant size reduction and complete metabolic response to treatment, rendering the tumour resectable. Mutational analysis showed an activating KIT mutation in exon 11. The pathological appearance of the resected tumour was heterogeneous with extensive necrosis, cystic and myxoid change, extensive hypocellularity, and patchy foci of residual viable tumour. The implications for this management option of radiological, pathological, and molecular assessment are discussed.

  • CT, computed tomography
  • GIST, gastrointestinal stromal tumour
  • PET, positron emission tomography
  • gastrointestinal stromal tumour
  • imatinib
  • neoadjuvant

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.